Post-marketing surveillance

Culliton, Barbara J.; Waterfall, Wallace K.
May 1980
British Medical Journal;5/10/1980, Vol. 280 Issue 6224, p1175
Academic Journal
Focuses on the system for monitoring the use and effects of prescription drugs following marketing strategy in the United States. Methods of post-marketing surveillance of pharmaceutical; Emphasis of the Food and Druf Administration on pre-marketing phases of drug development; Creation of the Joint Commission on Prescription Drug Use.


Related Articles

  • DID YOU KNOW?  // HealthLeaders Magazine;Mar2009, Vol. 12 Issue 3, p14 

    The article looks at the higher spending of Americans on prescription drugs compared to other industrialized countries in Europe. According to a report, patients in the U.S. spend each year $98 billion on medications which are more than those of other countries. Also included is an overview of...

  • Postmarketing surveillance of sofosbuvir in Egypt.  // Reactions Weekly;Apr2015, Vol. 1547 Issue 1, p3 

    The article reports on the clarification of the Technical Committee at the Central Administration of Pharmaceutical Affairs on the requirements for postmarketing surveillance of sofosbuvir for hepatitis C in Egypt.

  • Consumo y gasto de fármacos antipsicóticos.  // Actas Espanolas de Psiquiatria;mar2005, Vol. 33 Issue 2, p64 

    INTRODUCTION: In recent years, new atypical antipsychotic drugs have been marketed. This study aims to analyze the evolution of the consumption pattern and pharmaceutical cost of the antipsychotic drugs during the last years and the impact that the new atypical antipsychotic drugs have had....

  • New therapeutic agents marketed in the second half of 2009: Part 1. Hussar, Daniel A. // Pharmacy Today;Mar2010, Vol. 16 Issue 3, p48 

    Objective: To provide information regarding the most important properties of the new therapeutic agents marketed in the second half of 2009. Data sources: Product labeling supplemented selectively with published studies and drug information reference sources. Study selection: By the author. Data...

  • Compassionate use of orphan drugs. Hyry, Hanna I.; Manuel, Jeremy; Cox, Timothy M.; Roos, Jonathan C. P. // Orphanet Journal of Rare Diseases;Aug2015, Vol. 10 Issue 1, p1 

    Background: EU regulation 726/2004 authorises manufacturers to provide drugs to patients on a temporary basis when marketing authorisation sought centrally for the entire EU is still pending. Individual Member States retain the right to approve and implement such 'compassionate use' programmes...

  • Drugs use pattern for uncomplicated malarial in medicine retail outlets of Enugu urban, southeast Nigeria: implications for malaria treatment policy. Ezenduka, Charles C.; Ogbonna, Brian O.; Ekwunife, Obinna I.; Okonta, Mathew J.; Esimone, Charles O. // Malaria Journal;2014, Vol. 13 Issue 1, p1 

    Background Malaria treatment policy recommends regular monitoring of drug utilization to generate information for ensuring effective use of anti-malarial drugs in Nigeria. This information is currently limited in the retail sewctor which constitute a major source of malaria treatment in Nigeria,...

  • Lilly deal could set the bar for disclosures. Arnold, Matthew // Medical Marketing & Media;Nov2008, Vol. 43 Issue 11, p34 

    The article focuses on the settlement deal of Eli Lilly & Co. with the U.S. over off-label Zyprexa drug marketing. The deal can lead to disclosure of reporting requirements in future agreements with states. It includes provisions governing promotional activities, dissemination of medical...

  • All change for drug distribution? Kermani, Faiz // Pharmaceutical Technology Europe;Nov2008, Vol. 20 Issue 11, p17 

    The article examines the efficacy and impact of the changes in the distribution approach of drugs in Europe and the U.S. on the economic and financial condition of the pharmaceutical companies in 2008. Distribution systems of drugs directly affects the reliability and market positioning of...

  • Research & Markets: China Oral Hypoglyceimic Agents (OHAs) Industry Report 2010.  // Biomedical Market Newsletter;4/7/2011, p120 

    The article focuses on the addition by Research & Markets Ltd. of the China Oral Hypoglyceimic Agents (OHAs) Industry Report 2010 to its offering. It states that the report probes into the competition and status quo pattern of the industry, hospitals' drug use, and development potential of OHAS...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics